Anti-CD40 antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-12365740-B2
Application number	US-202017594255-A
Country	US
Kind code	B2
Filing date	Apr 10, 2020
Priority date	Apr 10, 2019
Publication date	Jul 22, 2025
Grant date	Jul 22, 2025

Abstract

The present invention relates to novel antibodies and antibody fragments that specifically bind to CD40, and compositions, medicaments, combination products and kits comprising the antibodies or antibody fragments. Furthermore, the invention relates to nucleic acids encoding said antibodies or antibody fragments thereof and host cells comprising the same, as well as related uses. Furthermore, the invention relates to therapeutic and diagnostic uses of these antibodies and antibody fragments.

First claim

The invention claimed is:

1. An antibody or antigen-binding fragment thereof that binds to CD40, comprising
(i) a heavy chain variable (VH) region comprising the 3 complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3 of the heavy chain variable region as set forth in SEQ ID NO:13, 58, 60 or 62 and a light chain variable (VL) region comprising the 3 CDRs LCDR1, LCDR2 and LCDR3 of the light chain variable region as set forth in SEQ ID NO:15, 64 or 66;
(ii) a VH region comprising the 3 CDRs HCDR1, HCDR2 and HCDR3 of the heavy chain variable region as set forth in SEQ ID NO: 13 and a VL comprising the 3 CDRs LCDR1, LCDR2 and LCDR3 of the light chain variable region as set forth in SEQ ID NO: 15;
(iii) a VH region comprising the 3 CDRs HCDR1, HCDR2 and HCDR3 of the heavy chain variable region as set forth as SEQ ID NO: 58 and a VL region comprising the 3 CDRs LCDR1, LCDR2 and LCDR3 of the light chain variable region as set forth as SEQ ID NO: 64;
(iv) a VH region comprising the 3 CDRs HCDR1, HCDR2 and HCDR3 of the heavy chain variable region as set forth as SEQ ID NO:60 or 62 and a VL region comprising the 3 CDRs LCDR1, LCDR2 and LCDR3 of the light chain variable region as set forth as SEQ ID NO:66; or
(v) a VH region comprising the 3 CDRs HCDR1, HCDR2 and HCDR3 of the heavy chain variable region as set forth in SEQ ID NO: 14 and a VL region comprising the 3 CDRs LCDR1, LCDR2 and LCDR3 of the light chain variable region as set forth in SEQ ID NO: 16.

2. An antibody or antigen-binding fragment thereof that binds to CD40, comprising
(i) a VH region comprising HCDR1, HCDR2 and HCDR3 comprising the amino acid sequences of SEQ ID NO:1, 3 and 5, respectively;
(ii) a VH region comprising HCDR1, HCDR2 and HCDR3 comprising the amino acid sequences of SEQ ID NO:1, 3 and 51, respectively; or
(iii) a VH region comprising HCDR1, HCDR2 and HCDR3 comprising the amino acid sequences of SEQ ID NO:1, 3 and 52, respectively

and
(i) a VL region comprising LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NO:7, 9 and 11, respectively;
(ii) a VL region comprising LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NO:7, 9 and 53, respectively; or
(iii) a VL region comprising LCDR1, LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NO:7, 9 and 54, respectively.

3. The antibody or antigen-binding fragment thereof of claim 1 , wherein,
(a) the VH region
(i) comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with an amino acid sequence selected from the group consisting of SEQ ID NO:13, 58, 60, 62, and 14;
(ii) comprises an amino acid sequence selected from the group consisting of SEQ ID NO:13, 58, 60, 62, and 14; or
iii) comprises an amino acid sequence having 1 or more amino acid alterations as compared to an amino acid sequence selected from the group consisting of SEQ ID NOs:13, 58, 60, 62, and 14;

and/or
(b) the VL region
(i) comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with an amino acid sequence selected from the group consisting of SEQ ID NO:15, 64, 66, and 16;
(ii) comprises an amino acid sequence selected from the group consisting of SEQ ID NO:15, 64, 66, and 16; or
(iii) comprises an amino acid sequence having 1 or more amino acid alterations as compared to an amino acid sequence selected from the group consisting of SEQ ID NO:15, 64, 66, and 16.

4. The antibody or antigen-binding fragment thereof of claim 3 , wherein
(i) the VH region comprises the amino acid sequence of SEQ ID NO: 13, 58, 60 or 62 and the VL region comprises an amino acid sequence selected from SEQ ID NO: 15, 64 or 66;
(ii) the VH region comprises the amino acid sequence of SEQ ID NO: 13 and the VL region comprises the amino acid sequence of SEQ ID NO: 15;
(iii) the VH region comprises the amino acid sequence of SEQ ID NO:58 and the VL region comprises the amino acid sequence of SEQ ID NO:64;
(iv) the VH region comprises the amino acid sequence of SEQ ID NO: 60 and the VL region comprises the amino acid sequence of SEQ ID NO: 66;
(v) the VH region comprises the amino acid sequence of SEQ ID NO:62 and the VL region comprises the amino acid sequence of SEQ ID NO:66; or
(vi) the VH region comprises the amino acid sequence of SEQ ID NO: 14 and the VL region comprises the amino acid sequence of SEQ ID NO: 16.

5. The antibody or antigen-binding fragment thereof of claim 1 , comprising a heavy chain and/or a light chain, wherein
(a) the heavy chain
(i) comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with an amino acid sequence selected from the group consisting of SEQ ID NO:17, 18, 19, 67, 69, 70, and 20;
(ii) comprises an amino acid sequence selected from the group consisting of SEQ ID NO:17, 18, 19, 67, 69, 70, and 20; or
(iii) comprises an amino acid sequence having 1 or more amino acid alterations as compared to an amino acid sequence selected from the group consisting of SEQ ID NOs:17, 18, 19, 67, 69, 70, and 20;

and/or
(b) the light chain
(i) comprises an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with an amino acid sequence selected from the group consisting of SEQ ID NO:21, 68, 71, and 22;
(ii) comprises an amino acid sequence selected from the group consisting of SEQ ID NO:21, 68, 71, and 22; or
(iii) comprises an amino acid sequence having 1 or more amino acid alterations as compared to an amino acid sequence selected from the group consisting of SEQ ID NOs: 21, 68, 71, and 22.

6. The antibody or antigen-binding fragment thereof of claim 5 , wherein
(i) the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:17, 18, 19, 67, 69, and 70 and the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:21, 68, and 71,
(ii) the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:17, 18, and 19 and the light chain comprises the amino acid sequence of SEQ ID NO:21;
(iii) the heavy chain comprises the amino acid sequence of SEQ ID NO:67 and the light chain comprises the amino acid sequence of SEQ ID NO:68;
(iv) the heavy chain comprises the amino acid sequence selected from SEQ ID NO:69 or 70 and the light chain comprises the amino acid sequence of SEQ ID NO:71; or
(v) the heavy chain comprises the amino acid sequence of SEQ ID NO: 20 and the light chain comprises the amino acid sequence of SEQ ID NO: 22.

7. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is a monoclonal antibody.

8. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is a humanized antibody or a human antibody or a chimeric antibody.

9. An isolated nucleic acid encoding the antibody or antigen-binding fragment thereof of claim 1 .

10. A vector comprising the nucleic acid of claim 9 .

11. A host cell comprising the vector of claim 10 .

12. A method of preparing an antibody or antigen-binding fragment thereof that binds CD40, the method comprising culturing a host cell comprising a nucleic acid encoding the antibody or antigen-binding fragment thereof of claim 1 , under conditions suitable for expression of the antibody or antigen-binding fragment thereof, and the method further comprising recovering the antibody or antigen-binding fragment thereof from the host cell.

13. An immunoconjugate comprising the antibody or antigen-binding fragment thereof of claim 1 and an additional agent.

Assignees

• Univ Nankai

Inventors

• Zhang Hongkai
• Wang Yuan

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/75

  Agonist effect on antigen · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title